Business, energy, technology, markets and global industry news from Business News Today

Jay Parrish

Pharma & Biotech

Pretzel Therapeutics receives UK trial authorisation for PX578 ahead of Phase 2 POLG disease study

Pretzel Therapeutics gains UK trial authorisation for PX578, paving the way for Phase 2 testing in POLG disease before year-end 2026.

Read More